World Pharmacovigilance Markets in Lifesciences

Product Code FRS01090
Publication Date December 2008
Publisher Frost & Sullivan
Product Type Report
Pages 83
ISBN Number not applicable
Change currency
PDF £4,110.00 €4,949 $6,499 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

World Pharmacovigilance Markets in Lifesciences

Outsourcing/Offshoring Environment Offers Considerable Potential for Pharmacovigilance Market

The challenge to manage adverse events in an optimal and efficient way and, at the same time, adhere to regulatory requirements has dictated the need for cutting edge pharmacovigilance tools and technologies.

"Regulatory bodies such as the Food & Drug Administration (FDA) and EMEA are intensifying safety regulations, thereby boosting the adoption rates of pharmacovigilance systems by pharmaceutical companies," notes the analyst of this research. "The need to operate in a cost-effective way is inducing pharmaceutical companies to outsource/offshore their pharmacovigilance operations." For large companies, the volume of adverse events is sizeable. Even a product from a mid-size company can generate a high volume of adverse events. There is significant potential for outsourcing/offhsoring for mid-sized companies as well.

Most top pharmaceutical companies have well-established systems and processes. Consequently, they are not willing to replace these systems as this entails high costs and is also time consuming. Moreover, the migration of data from one system to another tends to be expensive for most companies. Aligning existing processes to fit in the new system is difficult.

Vendors should educate pharmaceutical companies about technology implications and its importance in their day-to-day operations. This will be necessary to overcoming prevailing skepticism about new technology and its merits. They should conduct seminars and conferences to trigger interest and make pharmaceutical companies understand that technology that functions optimally can offer substantial return on investments (ROI).

"There will be advances in data integration that will support more flexible decision making on drug safety issues," remarks the analyst. "There is significant scope to extend pharmacovigilance systems to boost their integration with a range of other data sources such as medical records and clinical data."

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following regions in this research:

  • Europe
  • North America
  • Japan

Technologies

The following technologies are covered in this research:

  • Drug safety database systems
  • Signal detection systems

Contents

  • 1. Executive Summary
  • 2. Research Scope and Methodology
  • 3. Glossary
  • 4. Introduction and Background
  • 5. Market Dynamics
  • 6. Market Engineering Measurements
  • 7. Strategic Recommendations
  • 8. Key Industry Participants
  • 9. Decision Support Database
  • 10. Market Forecasts
  • 11. Strategic Recommendations
  • 12. Key Industry Participants
  • 13. Decision Support Databases